These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 11739902)
1. Optimized linker sequences for the expression of monomeric and dimeric bispecific single-chain diabodies. Völkel T; Korn T; Bach M; Müller R; Kontermann RE Protein Eng; 2001 Oct; 14(10):815-23. PubMed ID: 11739902 [TBL] [Abstract][Full Text] [Related]
2. Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin gamma1 Fc or CH3 region. Alt M; Müller R; Kontermann RE FEBS Lett; 1999 Jul; 454(1-2):90-4. PubMed ID: 10413102 [TBL] [Abstract][Full Text] [Related]
3. Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives. Stork R; Campigna E; Robert B; Müller D; Kontermann RE J Biol Chem; 2009 Sep; 284(38):25612-9. PubMed ID: 19628871 [TBL] [Abstract][Full Text] [Related]
4. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. Müller D; Karle A; Meissburger B; Höfig I; Stork R; Kontermann RE J Biol Chem; 2007 Apr; 282(17):12650-60. PubMed ID: 17347147 [TBL] [Abstract][Full Text] [Related]
5. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics. Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309 [TBL] [Abstract][Full Text] [Related]
6. Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody. Le Gall F; Reusch U; Little M; Kipriyanov SM Protein Eng Des Sel; 2004 Apr; 17(4):357-66. PubMed ID: 15126676 [TBL] [Abstract][Full Text] [Related]
7. "BIClonals": Production of Bispecific Antibodies in IgG Format in Transiently Transfected Mammalian Cells. Litvak-Greenfeld D; Vaks L; Dror S; Nahary L; Benhar I Methods Mol Biol; 2019; 1904():431-454. PubMed ID: 30539485 [TBL] [Abstract][Full Text] [Related]
8. N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies. Stork R; Zettlitz KA; Müller D; Rether M; Hanisch FG; Kontermann RE J Biol Chem; 2008 Mar; 283(12):7804-12. PubMed ID: 18211902 [TBL] [Abstract][Full Text] [Related]
9. Cloning, expression, purification and characterization of a bispecific single-chain diabody against fluoroquinolones and sulfonamides in Escherichia coli. Chen M; Wen K; Tao X; Xie J; Wang L; Li Y; Ding S; Jiang H Protein Expr Purif; 2014 Aug; 100():19-25. PubMed ID: 24816423 [TBL] [Abstract][Full Text] [Related]
10. Unexpected recombinations in single chain bispecific anti-CD3-anti-CD33 antibodies can be avoided by a novel linker module. Stamova S; Cartellieri M; Feldmann A; Arndt C; Koristka S; Bartsch H; Bippes CC; Wehner R; Schmitz M; von Bonin M; Bornhäuser M; Ehninger G; Bachmann M Mol Immunol; 2011 Dec; 49(3):474-82. PubMed ID: 22014687 [TBL] [Abstract][Full Text] [Related]
11. The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein. Hopp J; Hornig N; Zettlitz KA; Schwarz A; Fuss N; Müller D; Kontermann RE Protein Eng Des Sel; 2010 Nov; 23(11):827-34. PubMed ID: 20817756 [TBL] [Abstract][Full Text] [Related]
12. Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv. Korn T; Nettelbeck DM; Völkel T; Müller R; Kontermann RE J Gene Med; 2004 Jun; 6(6):642-51. PubMed ID: 15170735 [TBL] [Abstract][Full Text] [Related]
14. Cytotoxic enhancement of a bispecific diabody by format conversion to tandem single-chain variable fragment (taFv): the case of the hEx3 diabody. Asano R; Ikoma K; Shimomura I; Taki S; Nakanishi T; Umetsu M; Kumagai I J Biol Chem; 2011 Jan; 286(3):1812-8. PubMed ID: 21097496 [TBL] [Abstract][Full Text] [Related]
15. The role of valency in the selection of anti-carbohydrate single-chain Fvs from phage display libraries. MacKenzie R; To R J Immunol Methods; 1998 Nov; 220(1-2):39-49. PubMed ID: 9839924 [TBL] [Abstract][Full Text] [Related]
16. The crystal structure of an anti-CEA scFv diabody assembled from T84.66 scFvs in V(L)-to-V(H) orientation: implications for diabody flexibility. Carmichael JA; Power BE; Garrett TP; Yazaki PJ; Shively JE; Raubischek AA; Wu AM; Hudson PJ J Mol Biol; 2003 Feb; 326(2):341-51. PubMed ID: 12559905 [TBL] [Abstract][Full Text] [Related]
17. Effects of different interchain linkers on biological activity of an anti-prostate cancer single-chain bispecific antibody. Hao CH; Han QH; Shan ZJ; Hu JT; Zhang N; Zhang XP Theor Biol Med Model; 2015 Aug; 12():14. PubMed ID: 26246000 [TBL] [Abstract][Full Text] [Related]
18. [Construction and expression of an anti-EGFR/anti-KDR bispecific single-chain diabody]. Zhou YQ; Zhang J; Jin HZ; He Y; Wang T; Wang M Yao Xue Xue Bao; 2012 Oct; 47(10):1317-22. PubMed ID: 23289143 [TBL] [Abstract][Full Text] [Related]
19. Structural diversity and flexibility of diabodies. Kwon NY; Kim Y; Lee JO Methods; 2019 Feb; 154():136-142. PubMed ID: 30261312 [TBL] [Abstract][Full Text] [Related]
20. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. Kipriyanov SM; Moldenhauer G; Schuhmacher J; Cochlovius B; Von der Lieth CW; Matys ER; Little M J Mol Biol; 1999 Oct; 293(1):41-56. PubMed ID: 10512714 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]